Anti-FGFR2/CD332 Antibody (Bemarituzumab)
Catalog No.
F2042
Anti-FGFR2/CD332 Antibody (Bemarituzumab)
Featured Products
Bemarituzumab is a first-in-class humanized IgG1 monoclonal antibody directed against FGFR2b, a FGF receptor. Bemarituzumab prevents fibroblast growth factor from binding and activating FGFR2b. Bemarituzumab has the potential to be used in cancer research.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
144 kDa
Dry ice
1952272-74-0
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
HGS1036, HGS 1036, FP-1039
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P21802
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
SNU-16 cells were stained with Anti-FGFR2/CD332 Antibody (Bemarituzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS
FGFR2 / CD332
Please avoid freeze-thaw cycles.